Acting through ETA receptors, ET-1 appears to be central in cancer-induced osteoblastic lesions.[36] In animal models, the selective ETA receptor antagonist Atrasentan significantly reduced the osteoblastic response occurring from a ET-1-secreting tumor. The gene discussed is EDN1; the disease is cancer.